Palladio Biosciences, Inc., a private, venture capital-backed biotech company, was founded in 2015 to develop transformative medicines for orphan diseases of the kidney.
Our first product, lixivaptan, is in Phase 2 development for the treatment of polycystic kidney disease (PKD). PKD is one of the most common, life-threatening genetic diseases. PKD causes numerous fluid-filled cysts to grow in both kidneys. It is a life-limiting, chronic and progressive disease. PKD is the 4th leading cause of kidney failure and carries a significant financial and emotional burden, affecting entire families.